Allan Coukell is Pew’s senior director for health programs. He oversees initiatives related to drug and medical device innovation and safety, medical conflicts-of-interest, the pharmaceutical supply chain, pharmacy compounding, antibiotic resistance, prescription drug abuse, FDA, specialty drugs, food safety, school nutrition, as well as other efforts related to health costs and care delivery.
Prior to joining Pew, he practiced as a clinical pharmacist in oncology at the London Health Sciences Center and Ontario Regional Cancer Center, served as a senior medical writer and editor with the medical journal publisher Adis International, and covered health and science as a reporter and producer for WBUR (NPR) in Boston and Radio New Zealand. He is Vice Chair of the Medical Device Innovation Consortium and a board member of the Reagan Udall Foundation for the FDA. He served previously as consumer representative on the FDA’s Cardiovascular and Renal Drugs Advisory Committee.
Many proposed policies to reduce Medicare drug spending would require new legislation, but it’s possible the program could achieve some savings with an existing approach known as the national coverage determination (NCD) process. Read More
U.S. policymakers and patients continue to grapple with rising pharmaceutical spending, which accounted for $310 billion in 2015, an increase of almost 9 percent from the previous year. And costs are expected to continue to rise as high-priced brand-name and specialty medications hit the market. New branded drugs accounted for $24 billion in spending in 2015, while Medicare costs for specialty... Read More
Scientific, economic, and regulatory barriers have led many major pharmaceutical companies to limit or stop investing in antibiotic innovation, just as the rise of resistant “superbugs” makes it more important than ever to develop novel antimicrobial drugs. The world needs new, targeted scientific research and innovative policies to revitalize the drug pipeline, produce new... Read More